Atossa Genetics (NASDAQ:ATOS) Downgraded to Strong Sell Rating by Zacks Research

Key Points

• Zacks Research downgraded Atossa Genetics from a "hold" to a "strong sell" rating, reflecting growing concerns about the company's stock performance.
• Atossa Genetics reported a quarterly loss of ($0.07) earnings per share, missing the expected consensus estimate, which raises questions about its financial health moving forward.
• Institutional investors have shown varied interest, with recent acquisitions indicating that there is still some confidence in the company's potential despite its current challenges.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other brokerages have also weighed in on ATOS. Weiss Ratings restated a "sell (d-)" rating on shares of Atossa Genetics in a research note on Wednesday, October 8th. Ascendiant Capital Markets increased their price objective on shares of Atossa Genetics from $7.50 to $7.75 and gave the stock a "buy" rating in a report on Monday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $6.25.

Atossa Genetics Trading Down 1.9%

NASDAQ:ATOS opened at $1.03 on Monday. The stock has a market capitalization of $133.05 million, a P/E ratio of -4.48 and a beta of 1.11. Atossa Genetics has a 1 year low of $0.55 and a 1 year high of $1.66. The firm has a 50 day moving average of $0.84 and a 200-day moving average of $0.82.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). As a group, analysts forecast that Atossa Genetics will post -0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Hudson Bay Capital Management LP bought a new position in Atossa Genetics in the 2nd quarter worth approximately $26,000. Catalyst Funds Management Pty Ltd acquired a new stake in Atossa Genetics during the 2nd quarter worth $49,000. Bank of America Corp DE grew its holdings in Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company's stock worth $83,000 after acquiring an additional 35,629 shares during the period. Nuveen LLC acquired a new stake in Atossa Genetics during the 1st quarter worth $115,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Atossa Genetics by 40.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company's stock worth $284,000 after acquiring an additional 120,934 shares during the period. Institutional investors own 12.74% of the company's stock.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.